Compare EPRT & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPRT | NUVL |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | 228 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 7.2B |
| IPO Year | 2018 | 2021 |
| Metric | EPRT | NUVL |
|---|---|---|
| Price | $30.14 | $88.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | $36.79 | ★ $134.75 |
| AVG Volume (30 Days) | ★ 1.3M | 757.8K |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | ★ 11.30 | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $561,219,000.00 | N/A |
| Revenue This Year | $17.12 | N/A |
| Revenue Next Year | $16.27 | $1,239.49 |
| P/E Ratio | $108.11 | ★ N/A |
| Revenue Growth | ★ 24.82 | N/A |
| 52 Week Low | $28.95 | $71.14 |
| 52 Week High | $34.73 | $113.02 |
| Indicator | EPRT | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 34.83 |
| Support Level | $29.24 | $74.80 |
| Resistance Level | $30.39 | $109.45 |
| Average True Range (ATR) | 0.52 | 4.73 |
| MACD | -0.08 | -1.67 |
| Stochastic Oscillator | 28.04 | 3.63 |
Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses. The Company generally invests in and leases freestanding, single-tenant commercial real estate facilities where a tenant services its customers and conducts activities that are essential to the generation of the tenant's sales and profits.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.